Edition:
United States

NuVasive Inc (NUVA.OQ)

NUVA.OQ on NASDAQ Stock Exchange Global Select Market

65.86USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$65.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
249,353
52-wk High
$69.47
52-wk Low
$36.81

NUVA.OQ

Chart for NUVA.OQ

About

Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company's spine surgery products line offerings include... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $3,228.83
Shares Outstanding(Mil.): 50.35
Dividend: --
Yield (%): --

Financials

  NUVA.OQ Industry Sector
P/E (TTM): 81.39 32.25 29.87
EPS (TTM): 0.79 -- --
ROI: 3.23 13.46 14.95
ROE: 6.04 17.16 16.29

BRIEF-Nuvasive repurchased about $49.6 mln in aggregate principal amount of its 2.75 PCT convertible senior notes due 2017

* Nuvasive-From Nov 11 to nov 28, repurchased about $49.6 million in aggregate principal amount of its 2.75% convertible senior notes due 2017 - SEC filing

Nov 28 2016

BRIEF-Jana Partners cuts sole share stake in Alphabet, takes sole share stake in Mondelez International

* Jana Partners LLC takes sole share stake of 111,127 shares in Sage Therapeutics Inc

Nov 14 2016

Federal Circuit affirms invalidity of NuVasive spine implant patent

A U.S. appeals court on Wednesday upheld a decision by a patent appeal board holding most of a NuVasive Inc spine implant patent invalid, which NuVasive continued to appeal despite having settled with the company that originally challenged the patent, Medtronic Plc.

Nov 10 2016

BRIEF-Nuvasive secures magnetic resonance FDA conditional clearance for Magec system

* Nuvasive secures magnetic resonance (mr) fda conditional clearance for magec system

Oct 27 2016

BRIEF-Nuvasive Q3 NON-GAAP Earnings Per Share $0.40

* Reiterated full year 2016 financial guidance in line with prior expectations, with exception of revenue

Oct 25 2016

BRIEF-NuVasive receives FDA 510(k)clearance

* Receives FDA 510(k) clearance reinforcing comprehensive portfolio supporting pediatric, adolescent and adult spinal deformity patients Source text for Eikon: Further company coverage:

Sep 19 2016

BRIEF-NuVasive appoints Jason M. Hannon as president and COO

* Nuvasive names Jason M. Hannon president and chief operating officer; Patrick S. Miles assumes role of vice chairman

Sep 12 2016

BRIEF-Michael D O'halleran and Patrick S Miles elected to Nuvasive board

* Michael D. O'halleran and Patrick S. Miles elected to Nuvasive board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Aug 01 2016

BRIEF-NuVasive - sees 2016 revenue of approximately $962 mln

* FY2016 earnings per share view $1.51, revenue view $936.0 million -- Thomson Reuters I/B/E/S

Jul 26 2016

NuVasive settles spinal surgery patent fight with Medtronic

Medical device maker NuVasive Inc will pay rival Medtronic Plc $45 million to settle a longstanding patent fight related to spinal surgery technology, NuVasive said on Thursday.

Jun 30 2016

Earnings vs. Estimates